medic
colleg
hospit
april
decemb
retrospect
analyz
use
immunohistochem
analys
b
cell
count
lymphoid
follicl
perivascular
interstiti
peribronchiolar
region
lung
tissur
lymphocyt
mainli
present
lymphoid
follicl
number
follicular
lymphocyt
higher
fibros
cellular
nsip
pattern
vs
mm
p
year
therapi
follicular
lymphocyt
significantli
higher
patient
whose
forc
vital
capac
fvc
worsen
compar
improv
p
addit
follicular
lymphocyt
neg
correl
posttreat
percentag
chang
fvc
rho
p
howev
follicular
lymphocyt
correl
surviv
result
suggest
pulmonari
follicular
lymphocyt
correl
fibros
pattern
nsip
predict
less
clinic
improv
treatment
nonspecif
interstiti
pneumonia
nsip
interstiti
lung
diseas
ild
may
idiopath
secondari
connect
tissu
diseas
toxin
numer
caus
although
aetiolog
clinic
cours
highli
heterogen
nsip
histopatholog
characteris
lymphocyt
interstiti
infiltr
occasion
foci
fibroblast
variabl
collagen
deposit
precis
mechan
nsip
unclear
inflamm
appear
consist
present
lung
affect
patient
thu
medic
treatment
nsip
typic
base
glucocorticoid
without
cytotox
agent
besid
capac
antibodi
secret
b
lymphocyt
act
antigenpres
cell
lymphocyt
provid
addit
costimulatori
signal
produc
divers
inflammatori
regulatori
cytokin
express
b
cell
begin
late
prebcel
stage
bone
marrow
maintain
bcell
differenti
develop
peripheri
express
surfac
downregul
antibodysecret
plasmablast
extinguish
plasma
cell
b
lymphocyt
associ
number
inflammatori
respiratori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
hypersensit
pneumon
sarcoidosi
lung
transplant
reject
b
lymphocyt
also
play
role
publish
xx
xx
xxxx
open
wwwnaturecomscientificreport
develop
autoimmun
diseas
bcelltarget
therapi
effect
treatment
human
autoimmun
diseas
studi
bcell
involv
ild
limit
examin
diseas
lung
patient
shown
presenc
highli
abnorm
intrapulmonari
bcell
aggreg
anim
model
studi
indic
potenti
link
bcell
hyperact
fibrosi
lymphocyt
aggreg
compris
b
lymphocyt
present
patient
idiopath
pulmonari
fibrosi
ipf
activ
cellular
inflamm
continu
ipf
even
sever
end
stage
infiltr
b
lymphocyt
also
present
lung
patient
idiopath
nsip
rheumatoid
arthritisassoci
nsip
usual
interstiti
pneumonia
howev
precis
mechan
bcell
involv
nsip
remain
unknown
addit
studi
evalu
relationship
blymphocyt
infiltr
lung
tissu
clinic
outcom
progress
nsip
studi
investig
potenti
import
b
cell
nsip
hypothesis
bcell
infiltr
lung
may
correl
clinic
cours
nsip
use
immunohistochem
analys
b
cell
quantifi
store
tissu
specimen
patient
nsip
relationship
bcell
distribut
clinic
outcom
explor
patient
diagnost
criteria
april
decemb
patient
peke
union
medic
colleg
hospit
diagnos
nsip
base
surgic
lung
biopsi
attend
followup
appoint
pulmonari
function
test
chest
comput
tomographi
ct
scan
lung
specimen
patient
avail
immunohistochem
analys
patient
referr
case
hospit
patient
exclud
due
use
immunosuppress
therapi
lung
biopsi
remain
patient
includ
studi
clinic
featur
radiolog
imag
patholog
find
review
analys
nsip
diagnos
base
patholog
find
accord
american
thorac
societyeuropean
respiratori
societi
consensu
classif
nsip
classifi
three
clinic
subtyp
connect
tissu
diseas
ctd
associ
nsip
ctdnsip
autoantibodyposit
nsip
idiopath
nsip
patient
nsip
met
american
colleg
rheumatolog
criteria
ctd
assign
ctdnsip
group
patient
nsip
exhibit
autoimmun
featur
autoantibodi
posit
meet
american
colleg
rheumatolog
criteria
ctd
assign
autoantibodyposit
nsip
group
patient
consid
autoantibodyposit
antinuclear
antibodi
titr
well
posit
result
syndrom
antigen
syndrom
antigen
b
antism
antiribonucleoprotein
antibodi
antikeratin
antibodi
antiperinuclear
factor
anticycl
citrullin
peptid
antibodi
clinic
characterist
extract
follow
clinic
characterist
document
first
visit
age
sex
symptom
time
surgic
lung
biopsi
ie
cough
dyspnoea
wheez
smoke
statu
physic
examin
find
pulmonari
function
test
result
serolog
antibodi
test
result
pulmonari
physiolog
assess
forc
vital
capac
fvc
via
spirometri
total
lung
capac
via
plethysmographi
diffus
capac
lung
carbon
monoxid
dlco
measur
accord
american
thorac
societi
recommend
result
express
percentag
normal
predict
valu
classifi
patient
follow
group
accord
chang
fvc
predict
valu
month
steroid
therapi
fvc
improv
group
exhibit
fvc
improv
fvc
stabl
group
exhibit
fvc
chang
fvc
worsen
group
exhibit
fvc
worsen
highresolut
ct
scan
highresolut
ct
hrct
scan
chest
perform
patient
initi
evalu
hrct
scan
review
experienc
chest
radiologist
expertis
diffus
parenchym
lung
diseas
radiologist
blind
patient
ident
outcom
specif
hrct
find
document
index
scan
extent
groundglass
opac
ggo
reticul
consolid
honeycomb
score
scale
lobe
honeycomb
defin
cluster
cystic
air
space
mm
diamet
share
welldefin
wall
layer
subpleur
area
lung
treatment
respons
assess
accord
ct
find
year
steroid
therapi
patient
nsip
classifi
follow
ct
group
ct
exhibit
improv
groundglass
reticular
opac
ct
group
ct
exhibit
improv
ct
group
ct
exhibit
stabl
wors
find
lung
tissu
histolog
lung
tissu
specimen
independ
review
two
senior
pathologist
consensus
reach
regard
histolog
pattern
fifti
case
patholog
subclassifi
cellular
fibros
pattern
small
airway
defin
intern
diamet
mm
without
cartilag
small
blood
vessel
defin
intern
diamet
lung
biopsi
specimen
fix
neutralbuff
formalin
solut
cut
slice
embed
paraffin
section
thick
histolog
evalu
paraffin
section
immunohistochem
stain
manual
antibodi
clone
zeta
corp
sierra
madr
ca
dilut
antibodi
clone
zeta
corp
dilut
section
deparaffinis
rehydr
trisbuff
salin
tri
nacl
ph
min
endogen
peroxidas
block
hydrogen
peroxid
min
section
wash
trisbuff
salin
incub
primari
antibodi
appropri
dilut
h
incub
secondari
antibodi
min
final
detect
dab
stain
bcell
stain
monocyt
number
cell
posit
stain
dark
brown
analys
use
nanozoom
slide
scan
system
hamamatsu
photon
kk
hamamatsu
japan
anymicro
dss
pro
imag
analysi
system
yutianshijiweiy
inc
beij
china
four
microscop
region
analys
ie
lymphoid
follicl
perivascular
interstiti
peribronchiolar
region
biopsi
slide
contain
four
microscop
region
imag
obtain
region
slide
fig
least
six
highpow
field
magnif
analysi
area
approxim
mm
randomli
select
region
use
cell
count
receiv
diagnosi
nsip
patient
receiv
cours
oral
prednison
began
mgkgd
month
taper
everi
week
mgd
dose
decreas
initi
dose
everi
week
dose
maintain
mgd
surgic
lung
biopsi
patient
underw
followup
assess
everi
month
followup
includ
complet
blood
cell
count
liver
function
test
renal
function
test
chest
ct
scan
pulmonari
function
test
perform
month
treatment
interstiti
lung
diseas
clinic
peke
union
medic
colleg
hospit
valu
express
mean
standard
deviat
normal
distribut
data
median
nonnorm
distribut
data
rank
sum
test
use
nonnorm
distribut
data
wilcoxon
sign
rank
test
kruskalw
h
test
use
compar
two
group
two
group
data
respect
correl
coeffici
calcul
use
spearman
rank
method
first
univari
analysi
kaplanmei
method
categor
variabl
cox
proport
hazard
regress
model
continu
variabl
perform
explor
factor
influenc
surviv
includ
age
sex
baselin
fvc
dlco
follicular
b
lymphocyt
presenc
ctd
presenc
antibodi
clinic
subtyp
nsip
patholog
subtyp
nsip
next
cox
proport
hazard
regress
model
backward
method
wald
test
perform
includ
variabl
select
univari
analysi
overal
surviv
calcul
kaplanmei
estim
kaplanmei
method
logrank
test
use
compar
surviv
two
group
probabl
valu
obtain
twosid
test
statist
signific
set
p
spss
window
version
spss
inc
chicago
il
usa
use
statist
analys
inform
consent
use
patient
medic
record
obtain
everi
patient
andor
guardian
patient
admit
hospit
studi
approv
peke
union
medic
colleg
hospit
institut
review
board
refer
number
experi
perform
accord
relev
guidelin
regul
data
avail
dataset
gener
andor
analys
current
studi
avail
correspond
author
reason
request
clinic
featur
laboratori
find
fifti
patient
nsip
includ
clinic
radiolog
physiolog
measur
obtain
time
initi
visit
shown
tabl
mean
age
year
rang
year
patient
women
patient
compris
nonsmok
exsmok
current
smoker
median
durat
onset
respiratori
symptom
lung
biopsi
month
rang
month
twenti
patient
diagnos
ctdnsip
polymyositisdermatomyos
n
rheumatoid
arthriti
n
syndrom
n
system
sclerosi
n
twelv
patient
serolog
posit
least
one
autoantibodi
meet
diagnost
criteria
ctd
patient
serolog
neg
diagnos
idiopath
nsip
stain
lung
specimen
reveal
infiltr
lymphocyt
mainli
concentr
lymphoid
follicl
region
fig
tabl
addit
percentag
chang
fvc
treatment
neg
correl
follicular
lymphocyt
count
rho
p
fig
densiti
lymphocyt
infiltr
anatom
compart
associ
pulmonari
function
test
result
fig
better
surviv
patient
without
groundglass
opac
consolid
hrct
p
fig
univari
analysi
reveal
higher
mortal
risk
patient
lower
baselin
fvc
higher
erythrocyt
sediment
rate
age
sex
clinic
subtyp
nsip
ctdnsip
autoantibodyposit
nsip
idiopath
nsip
baselin
dlco
pao
lymphocyt
infiltr
lung
correl
surviv
multivari
analysi
use
cox
proport
hazard
regress
analysi
reveal
baselin
erythrocyt
sediment
rate
hazard
ratio
confid
interv
p
independ
risk
factor
surviv
baselin
fvc
hazard
ratio
confid
interv
p
protect
factor
surviv
present
studi
found
b
lymphocyt
mainli
distribut
lymphoid
follicl
lung
specimen
patient
nsip
studi
first
demonstr
higher
number
follicular
cell
present
fibros
cellular
nsip
cell
within
lymphoid
follicl
neg
correl
improv
fvc
year
therapi
nsip
pattern
histolog
characteris
vari
amount
interstiti
inflamm
fibrosi
uniform
appear
lymphocyt
infiltr
nsip
exhibit
elev
number
cell
addit
popul
rich
b
cell
addit
b
cell
mainli
accumul
lymphoid
follicl
nsip
associ
polymyositisdermatomyos
idiopath
nsip
rheumatoid
arthritisassoci
nsip
observ
markedli
increas
number
b
lymphocyt
mainli
distribut
lymphoid
follicl
nsip
includ
ctdnsip
autoantibodyposit
nsip
idiopath
nsip
confirm
previou
report
abnorm
bcell
aggreg
within
nsipaffect
lung
although
evid
increas
number
b
cell
ild
includ
nsip
chronic
lung
diseas
precis
mechan
unclear
inflammatori
process
leukocyt
infiltr
lung
often
assembl
structur
known
induc
bronchusassoci
lymphoid
tissu
ibalt
contain
bcellpredomin
follicl
surround
parafollicular
tcell
zone
dendrit
cell
ibalt
found
lung
biopsi
patient
hypersensit
pneumon
asthma
copd
ipf
ild
associ
system
sclerosi
rheumatoid
arthriti
syndrom
overexpress
proinflammatori
cytokin
receptor
tumour
necrosi
factor
lung
shown
induc
format
ibalt
absenc
antigen
pathogen
bcellactiv
factor
tumour
necrosi
factor
famili
baff
contribut
format
expans
pulmonari
lymphoid
follicl
promot
surviv
prolifer
follicular
b
cell
chemokin
drive
recruit
b
cell
circul
includ
involv
localis
within
ibalt
includ
well
previou
studi
shown
ibalt
contribut
local
product
autoantibodi
correl
local
patholog
particip
local
pathogenesi
wide
varieti
chronic
lung
diseas
although
precis
mechan
remain
poorli
understood
deserv
investig
although
studi
shown
presenc
highli
abnorm
intrapulmonari
bcell
aggreg
patient
nsip
discuss
inform
avail
regard
impact
bcell
compart
clinic
outcom
nsip
studi
first
demonstr
follicular
b
cell
lung
neg
correl
improv
fvc
therapi
indic
higher
number
b
cell
correl
lower
respons
therapi
poorer
clinic
cours
howev
follicular
b
cell
correl
surviv
erythrocyt
sediment
rate
independ
risk
factor
surviv
indic
system
inflam
might
correl
poor
outcom
although
precis
mechan
need
investig
recent
studi
indic
b
cell
also
associ
diseas
progress
patient
ipf
b
lymphocyt
lung
associ
rapid
declin
fvc
addit
plasma
concentr
bli
oblig
factor
bcell
surviv
differenti
shown
elev
patient
ipf
associ
poor
surviv
strong
correl
b
cell
ibalt
airway
sever
airflow
limit
patient
copd
addit
b
lymphocyt
play
role
autoimmun
diseas
percentag
activ
peripher
blood
b
lymphocyt
magnitud
bcell
differenti
correl
clinic
activ
autoimmun
diseas
rheumatoid
arthriti
system
lupu
erythematosu
result
previou
studi
appear
support
notion
b
cell
correl
poor
outcom
contribut
progress
variou
diseas
ild
autoimmun
diseas
studi
reveal
higher
number
lymphoid
follicular
b
cell
associ
fibros
nsip
suggest
possibl
contribut
pathogen
potenti
b
cell
fibrot
process
although
studi
limit
precis
pathophysiolog
remain
poorli
understood
evid
role
b
lymphocyt
variou
fibrot
lung
diseas
grow
defici
bcell
surfac
molecul
mice
reduc
suscept
bleomycininduc
fibrosi
wherea
overexpress
mice
aggrav
bleomycininduc
fibrosi
indic
potenti
link
b
cell
lung
fibrosi
previou
studi
ipf
reveal
lymphocyt
b
cell
numer
advanc
diseas
fibrosi
honeycomb
chang
earli
diseas
mous
model
silicainduc
lung
fibrosi
regulatori
b
cell
could
control
lung
inflamm
exacerb
lung
fibrosi
inhibit
thelper
respons
modul
thelper
balanc
bcell
prolifer
activ
significantli
induc
irradi
lung
fibrosispron
mice
suggest
possibl
role
b
cell
radiationinduc
fibros
alveol
b
lymphocyt
may
contribut
pathogenesi
fibros
mediastin
deplet
b
cell
effect
treat
diseas
togeth
previou
find
studi
provid
evid
b
cell
play
role
fibrot
diseas
specif
target
b
lymphocyt
may
explor
potenti
treatment
strategi
fibrot
diseas
studi
reveal
b
cell
may
play
role
progress
fibros
nsip
correl
poorer
therapeut
effect
patient
nsip
thu
altern
therapi
explor
deplet
cell
may
candid
therapi
nsip
rituximab
effect
depletor
cell
approv
treatment
rheumatoid
arthriti
system
vascul
sever
studi
reveal
monoclon
antibodi
effect
treatment
ctdassoci
ild
particularli
resist
steroid
cyclophosphamid
treatment
thu
antibcel
agent
eg
rituximab
other
develop
may
becom
therapeut
option
nsip
characteris
inflamm
fibrosi
autoimmun
featur
studi
sever
limit
first
retrospect
natur
second
sampl
size
limit
result
repres
experi
singl
centr
therefor
multicentr
studi
larger
cohort
requir
confirm
result
also
need
clarifi
relationship
b
cell
peripher
blood
b
cell
lung
tissu
greater
infiltr
cell
within
lymphoid
follicl
correl
fibros
pattern
nsip
predict
less
clinic
improv
treatment
underli
mechan
associ
unknown
studi
requir
find
illumin
potenti
novel
treatment
regimen
specif
target
b
cell
patient
nsip
